"Antiparkinson Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
| Descriptor ID |
D000978
|
| MeSH Number(s) |
D27.505.954.427.090.050
|
| Concept/Terms |
Antiparkinson Agents- Antiparkinson Agents
- Agents, Antiparkinson
- Antiparkinsonian Agents
- Agents, Antiparkinsonian
- Antiparkinsonians
- Antiparkinson Drugs
- Drugs, Antiparkinson
|
Below are MeSH descriptors whose meaning is more general than "Antiparkinson Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiparkinson Agents".
This graph shows the total number of publications written about "Antiparkinson Agents" by people in this website by year, and whether "Antiparkinson Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 3 | 1 | 4 |
| 1998 | 5 | 3 | 8 |
| 1999 | 4 | 1 | 5 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 6 | 0 | 6 |
| 2003 | 4 | 2 | 6 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 3 | 5 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 4 | 2 | 6 |
| 2009 | 3 | 2 | 5 |
| 2010 | 1 | 3 | 4 |
| 2011 | 2 | 3 | 5 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 2 | 4 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 2 | 1 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 2 | 3 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiparkinson Agents" by people in Profiles.
-
Device-aided therapies for Parkinson's disease: "All for one, one for all, that is our device". Parkinsonism Relat Disord. 2023 Nov; 116:105862.
-
Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease. Mov Disord. 2023 04; 38(4):688-692.
-
Quality Improvement in Neurology: 2020 Parkinson Disease Quality Measurement Set Update. Neurology. 2021 08 03; 97(5):239-245.
-
On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med. 2021 Sep; 133(7):721-727.
-
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation. Clin Pharmacol Ther. 2021 08; 110(2):508-518.
-
Gut bacterial deamination of residual levodopa medication for Parkinson's disease. BMC Biol. 2020 10 20; 18(1):137.
-
Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse Model of Parkinson's Disease Via Astrocytic GDNF. J Neuroimmune Pharmacol. 2019 09; 14(3):503-518.
-
Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun. 2019 01 18; 10(1):310.
-
Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
-
What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias. Mov Disord. 2017 04; 32(4):483-484.